Literature DB >> 16803899

Probing active site chemistry in SHV beta-lactamase variants at Ambler position 244. Understanding unique properties of inhibitor resistance.

Jodi M Thomson1, Anne M Distler, Fabio Prati, Robert A Bonomo.   

Abstract

Inhibitor-resistant class A beta-lactamases are an emerging threat to the use of beta-lactam/beta-lactamase inhibitor combinations (e.g. amoxicillin/clavulanate) in the treatment of serious bacterial infections. In the TEM family of Class A beta-lactamases, single amino acid substitutions at Arg-244 confer resistance to clavulanate inactivation. To understand the amino acid sequence requirements in class A beta-lactamases that confer resistance to clavulanate, we performed site-saturation mutagenesis of Arg-244 in SHV-1, a related class A beta-lactamase found in Klebsiella pneumoniae. Twelve SHV enzymes with amino acid substitutions at Arg-244 resulted in significant increases in minimal inhibitory concentrations to ampicillin/clavulanate when expressed in Escherichia coli. Kinetic analyses of SHV-1, R244S, R244Q, R244L, and R244E beta-lactamases revealed that the main determinant of clavulanate resistance was reduced inhibitor affinity. In contrast to studies in the highly similar TEM enzyme, we observed increases in clavulanate k(inact) for all mutants. Electrospray ionization mass spectrometry of clavulanate inhibited SHV-1 and R244S showed nearly identical mass adducts, arguing against a difference in the inactivation mechanism. Testing a wide range of substrates with C3-4 carboxylates in different stereochemical orientations, we observed impaired affinity for all substrates among inhibitor resistant variants. Lastly, we synthesized two boronic acid transition state analogs that mimic cephalothin and found substitutions at Arg-244 markedly affect both the affinity and kinetics of binding to the chiral, deacylation transition state inhibitor. These data define a role for Arg-244 in substrate and inhibitor binding in the SHV beta-lactamase.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16803899     DOI: 10.1074/jbc.M603222200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Structural study of phenyl boronic acid derivatives as AmpC beta-lactamase inhibitors.

Authors:  Donatella Tondi; Samuele Calò; Brian K Shoichet; Maria Paola Costi
Journal:  Bioorg Med Chem Lett       Date:  2010-04-09       Impact factor: 2.823

2.  Identification and characterization of beta-lactamase inhibitor protein-II (BLIP-II) interactions with beta-lactamases using phage display.

Authors:  N G Brown; T Palzkill
Journal:  Protein Eng Des Sel       Date:  2010-03-22       Impact factor: 1.650

3.  Use of novel boronic acid transition state inhibitors to probe substrate affinity in SHV-type extended-spectrum beta-lactamases.

Authors:  Jodi M Thomson; Fabio Prati; Christopher R Bethel; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

4.  Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.

Authors:  Krisztina M Papp-Wallace; Marisa L Winkler; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

5.  Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.

Authors:  Krisztina M Papp-Wallace; Christopher R Bethel; Anne M Distler; Courtney Kasuboski; Magdalena Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

6.  Strategic design of an effective beta-lactamase inhibitor: LN-1-255, a 6-alkylidene-2'-substituted penicillin sulfone.

Authors:  Priyaranjan Pattanaik; Christopher R Bethel; Andrea M Hujer; Kristine M Hujer; Anne M Distler; Magdalena Taracila; Vernon E Anderson; Thomas R Fritsche; Ronald N Jones; Sundar Ram Reddy Pagadala; Focco van den Akker; John D Buynak; Robert A Bonomo
Journal:  J Biol Chem       Date:  2008-10-27       Impact factor: 5.157

7.  Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.

Authors:  Marisa L Winkler; Elizabeth A Rodkey; Magdalena A Taracila; Sarah M Drawz; Christopher R Bethel; Krisztina M Papp-Wallace; Kerri M Smith; Yan Xu; Jeffrey R Dwulit-Smith; Chiara Romagnoli; Emilia Caselli; Fabio Prati; Focco van den Akker; Robert A Bonomo
Journal:  J Med Chem       Date:  2013-02-04       Impact factor: 7.446

8.  Interactions of oximino-substituted boronic acids and β-lactams with the CMY-2-derived extended-spectrum cephalosporinases CMY-30 and CMY-42.

Authors:  Stathis D Kotsakis; Emilia Caselli; Leonidas S Tzouvelekis; Efi Petinaki; Fabio Prati; Vivi Miriagou
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

9.  Penicillin sulfone inhibitors of class D beta-lactamases.

Authors:  Sarah M Drawz; Christopher R Bethel; Venkata R Doppalapudi; Anjaneyulu Sheri; Sundar Ram Reddy Pagadala; Andrea M Hujer; Marion J Skalweit; Vernon E Anderson; Shu G Chen; John D Buynak; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

10.  Substitutions at position 105 in SHV family β-lactamases decrease catalytic efficiency and cause inhibitor resistance.

Authors:  Mei Li; Benjamin C Conklin; Magdalena A Taracila; Rebecca A Hutton; Marion J Skalweit
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.